Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...
Merck (MRK) stock gains as new oral HIV tablet matches Gilead's (GILD) three-drug once-daily HIV pill Biktarvy in a Phase 3 ...
Merck's HIV pill met key efficacy and safety goals in Phase 3 trials, matching Biktarvy as the FDA reviews its application with a 2026 decision date.
On Oct. 6, Gilead Sciences GILD announced a settlement with three generic manufacturers, securing an agreement for them not to launch a generic version of the firm’s HIV drug Biktarvy in the United ...
Gilead Sciences, Inc.’s HIV franchise, led by Biktarvy, ensures stable cash flows through 2033, providing long-term visibility and a strong competitive advantage. The launch of Yeztugo, a biannual ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback